Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Cambridge University Hospitals NHS Foundation Trust: Clinical Trials & FDA Approval Profile

Cambridge University Hospitals NHS Foundation Trust (Global / Institutional) sponsors 20 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 6 active protocols (3 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)15.0%
Median Closed Enrollment vs National (145 pts)70 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Cambridge University Hospitals NHS Foundation Trust
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)20
Active Pipeline (Recruiting Now)6 (3)
Completed vs Stopped Early5 / 3 (15.0%)
Median Closed Actual Enrollment70 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Cambridge University Hospitals NHS Foundation Trust
Hospital Research SiteLocationShared Protocols
Addenbrooke's HospitalCambridge, Cambridgeshire6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Cambridge University Hospitals NHS Foundation Trust
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04870333PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -VPhase II/IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Cambridge University Hospitals NHS Foundation Trust Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI